Showing results (1251-1260 of 2,812) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|June 3, 2017
Cardiovascular pleiotropic effects of statins and new onset diabetes: is there a common link: do we need to evaluate the role of KATP channels?Devindra Sehra, Sudhish Sehra, Shiv Tej SehraExpert Opinion on Drug Safety|June 27, 2017
The French addictovigilance network clinical assessment: Z-drugs, true false twinsMorgane Rousselet, Fanny Feuillet, Marie Gerardin, et al.Expert Opinion on Drug Safety|December 22, 2009
Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infectionsElizabeth D Hermsen, Monica Hanson, Jayashri Sankaranarayanan, et al.Expert Opinion on Drug Safety|December 22, 2009
Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementiaTaher Darreh-Shori, Vesna JelicExpert Opinion on Drug Safety|December 17, 2009
Outcomes and safety of rapid desensitization for chemotherapy hypersensitivityTicha Limsuwan, Mariana C CastellsExpert Opinion on Drug Safety|December 17, 2009
Genetic predisposition of life-threatening antiepileptic-induced skin reactionsWen-Hung Chung, Shuen-Iu Hung, Yuan-Tsong ChenExpert Opinion on Drug Safety|December 17, 2009
Safety and efficacy of over-the-counter cough and cold medicines for use in childrenZdravko P Vassilev, Shaum Kabadi, Raul VillaExpert Opinion on Drug Safety|February 24, 2010
Remifentanil, a different opioid: potential clinical applications and safety aspectsCharalampos Stroumpos, Maria Manolaraki, Gregorios A PaspatisExpert Opinion on Drug Safety|June 14, 2018
A safety evaluation of guselkumab for the treatment of psoriasisM Galluzzo, S D'Adamio, E Campione, et al.Expert Opinion on Drug Safety|February 21, 2015
Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's diseaseMeir Kestenbaum, Stanley FahnPageof 282